Key facts
- Embio Diagnostics’s last known valuation is $5.7M (Dec 2021).
- It has raised $3.8M; the latest was Angel (individual) ($2.7M) in Dec 2025.
- Notable investors include ASBISC Enterprises, Chrysalis LEAP, Kinisis Ventures, Sasha Vezenkov.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Embio Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Embio Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Embio Diagnostics
Operator of a biotechnology company intended to design and develop innovative, portable, biosensor-based, and digital devices for rapid diagnostics. The company's devices can be used in the medical industry for fast detection and diagnosis for both professional and individual use, and offer biosensor-based, multi-use handheld chemical analyzer systems for rapid diagnostics in the field of food safety, enabling healthcare firms to help with the detection and monitoring of bacteria and viruses.
- Sector
- Healthcare
- HQ
- Nicosia, Cyprus
- Founded
- 2016
- Employees
- 25
- Website
- embiodiagnostics.eu/
- Ownership
- Privately Held (backing)
Embio Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Embio Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Embio Diagnostics in its N-PORT filings yet. We sweep new filings monthly.